The Society of Interventional Radiology (SIR) has published new practice guidance for the use of prostatic artery ...

By Sneha S K May 31 (Reuters) - Johnson & Johnson's prostate cancer drug Erleada used with hormone-blocking therapy six ...

CINCINNATI (WKRC) — A groundbreaking procedure is offering new hope for men suffering from benign prostate hyperplasia (BPH), a condition affecting up to half of all men. Keith Neer, a patient who ...

A new technology called HYDROS Robotic system is being used to treat BPH  in a non-invasive way through a procedure in a ...

Profound Medical Corp. (NASDAQ:PROF) is one of the best Canadian stocks with huge upside potential. On June 10, Profound Medical announced the successful completion of the first commercial benign ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

The Society of Interventional Radiology (SIR) published new practice guidance for the use of prostatic artery embolization (PAE) to treat enlarged prostate (also called benign prostatic hyperplasia or ...

Johnson & Johnson said its prostate cancer drug Erleada, when used with hormone-blocking therapy before and after prostate ...

TORONTO, Nov. 28, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF) (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets ...

Johnson & Johnson’s PROTEUS Phase 3 trial shows apalutamide + hormone therapy before/after surgery improves outcomes in ...

The Expander-2 trial randomly assigned men with BPH symptoms at 23 sites in the US and Canada to receive a temporary nitinol urethral implant, Urocross Expander, or a sham procedure.